$118.280
-2.933 (-2.48%)At close
HAE News
HAE Events
Haemonetics Stock Rises 16% to $117.99
Haemonetics is up 16.0%, or $16.28 to $117.99.
Haemonetics Stock Rises 15.8% to $117.75
Haemonetics is up 15.8%, or $16.04 to $117.75.
Stock Futures Lower as Oil Prices and Treasury Yields Rise
Stock futures are lower as a renewed jump in oil prices and Treasury yields revives inflation concerns. Brent crude jumped nearly 5% to above $105 a barrel, while WTI climbed toward $93 as concerns over renewed U.S.-Iran military action increased. The 10-year Treasury yield rose to around 5.34%, near its highest level since 2002, putting additional pressure on equities, particularly high-valuation technology stocks.The broader setup is increasingly a tug-of-war between strong expected earnings and deteriorating macro conditions. LSEG expects S&P 500 earnings to rise 30.6% in the third quarter, but the market is confronting a 10-year yield near 5.35%, oil above $100 and a Fed that still expects at least one more rate hike this year.In pre-market trading, S&P 500 futures fell 0.41%, Nasdaq futures fell 0.68% and Dow futures fell 0.68%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Haemoneticsup 17% after disclosing its entry into a non-exclusive supply agreement with CSL PlasmaWolfspeedup 16% after receiving a conditional loan commitment letter from the U.S. Department of War for up to $1.5B of long-term financingPalantirup 2% after Goldman Sachs upgraded the stock to Buy with a $230 price targetUP AFTER EARNINGS -Helen of Troyup 13%PepsiCoup 1%Applied Digitalup 1%DOWN AFTER EARNINGS -AngioDynamicsdown 2%Levi Straussdown 2%Tilraydown 1%
Haemonetics Enters Supply Agreement with CSL Plasma
In a regulatory filing, Haemonetics disclosed its entry into a non-exclusive supply agreement with CSL Plasma, under which CSL may utilize the company's NexSys PCS devices with Persona PLUS technology and purchase related disposables in the United States. On October 8, CSL announced that it expects to complete the rollout of the Company's devices and disposables under the supply agreement by the end of calendar year 2027, and CSL has informed the company that it currently anticipates that the transition to the company's devices and disposables will occur at all of CSL's current U.S. plasma collection centers. The scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement, and the implementation details for the rollout are still to be determined by CSL and the company. Accordingly, the company is not updating its previously issued FY27 guidance at this time. The company expects to provide an update regarding the anticipated impact of the supply agreement on its FY27 financial results in connection with its second fiscal quarter earnings call in November.
Orchestra BioMed Receives $6.1M Milestone Payment
Orchestra BioMed (OBIO) announced the receipt of $6.1M as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical by Haemonetics (HAE). This second payment follows the approximately $5M upfront payment received in January and brings total cash proceeds received by Orchestra BioMed from the transaction to approximately $11M. The payment completes the approximately $11M in proceeds previously disclosed as expected during 2026. Orchestra BioMed remains eligible to receive up to approximately $10M in additional proceeds through future revenue earnouts, subject to the achievement of certain milestones, for total potential proceeds of up to $21M.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.